Pushing the heavy insurance card across the laminate pharmacy counter feels like a reflex, a learned behavior we’ve all been conditioned to believe is the only way to survive the American healthcare system. I watched the pharmacist’s brow furrow as the screen refreshed, a flickering blue light reflecting off her glasses. She hesitated, her fingers hovering over the “complete transaction” button for a full 5 seconds before she looked up.

She didn’t look at the screen; she looked at me. It was a look of quiet, professional conflict.

“With your insurance, the copay is $55,” she said, her voice dropping just enough to signal a change in the weather. Then, the pivot that shouldn’t have to be a secret: “But if you don’t use your insurance… if you just pay the cash price today, it’s $15.”

I stood there for 15 seconds, paralyzed by the math. My insurance-the high-premium, “gold-tier” plan I pay for every month-was effectively charging me a $40 surcharge for the privilege of using it. I wasn’t being helped by my coverage; I was being penalized by it.

This is the “clawback,” a term that sounds like something out of a horror movie because, for the average patient’s wallet, it absolutely is. It is the moment where the intermediary, the Pharmacy Benefit Manager (PBM), decides that the “negotiated rate” should actually be higher than the market rate, and they pocket the difference.

The Fountain Pen Restoration

This decoupling of price from value is a phenomenon I’ve been obsessing over lately, especially after I spent the weekend helping my friend Taylor Z. organize his workshop. Taylor is a fountain pen repair specialist, a man who lives in a world of microscopic tolerances and 75-year-old celluloid.

He had just finished a marathon session of organizing his client files by color-deep emerald for the nib restorations, a sharp crimson for the vintage vacuum-filler repairs. He likes things to make sense. He likes a system where the input directly correlates to the output.

As we sat among the scent of ink and old plastic, Taylor showed me a receipt for a common antibiotic he’d picked up 25 days prior. His copay was $35. The actual cost of the drug to the pharmacy was roughly $5. The PBM “clawed back” the extra $25 from the pharmacy’s account at the end of the month.

Taylor was outraged, not just at the money, but at the lack of precision. In his world, if a nib is misaligned by a fraction of a millimeter, the pen won’t write.

The History of Enforced Silence

For a long time, pharmacists were actually prohibited from telling you this. It was called a “gag clause.” If a pharmacist saw that you were about to pay a $45 copay for a drug that cost $15 out-of-pocket, they were contractually forbidden by the PBMs from mentioning it. They had to watch you overpay.

It wasn’t until 5 years ago, in 2018, that federal law finally stepped in to ban these clauses, but the habit of silence remains. Many pharmacists are still overworked, processing 325 prescriptions a day, and they simply don’t have the time to check the cash price versus the copay for every single person in line.

This creates a strange reality where “using your insurance” can be the most expensive way to buy medicine. We have forgotten that a middleman’s primary loyalty is to the transaction, not the traveler.

The Parasitic Cost of Tiering

The complexity is staggering. Take, for instance, a patient trying to navigate a parasitic infection or a complex digestive issue. They might be prescribed a specific treatment and find themselves staring at a bill that feels like a mortgage payment.

They might look for alternatives and search for a way to buy alinia online, realizing the answer to the high cost isn’t about the chemistry or the manufacturing-it’s about the tiering.

Insurance companies categorize drugs into “tiers.” If a drug is moved to a higher tier, your copay might skyrocket to $175 or even $575, regardless of whether the actual cost of making that drug has changed.

I’ve made this mistake myself. I remember once paying $125 for a generic skin cream because I assumed that if my insurance said that was my share, it must be a “discounted” rate. It wasn’t until 5 months later, when I was browsing a different pharmacy’s website, that I saw the exact same tube for $25 cash.

I felt like a fool. I had been paying for the illusion of coverage. I criticize the system for being opaque, yet I find myself still reaching for that plastic card every time, a victim of the very “security” I know is flawed. It’s a contradiction I haven’t quite resolved yet.

The Stripping of Layers

Taylor Z. looks at these things through the lens of restoration. When he fixes a pen, he strips it down to the feed and the breather tube. He removes the calcified ink that’s been blocking the flow for 45 years.

He thinks we need a similar restoration in healthcare pricing-a stripping away of the layers of PBMs, rebates, and hidden fees until we get back to the “feed,” the actual transaction between the patient and the provider.

The reality of modern pharmacy is that the “price” is a moving target. PBMs negotiate “rebates” from drug manufacturers. You would think these rebates would lower the price for the patient, but often, the opposite happens.

The manufacturer raises the “list price” so they can offer a bigger “rebate” to the PBM to ensure their drug is “preferred” on the insurance plan’s list. The patient, whose copay might be a percentage of that inflated list price, ends up paying more so that the middleman can “save” more.

The Grand Canyon of “Spread Pricing”

I once saw a spreadsheet-Taylor would have loved the color-coding on it-that showed the “spread pricing” models used by some PBMs. In one column, you had what the insurance company paid the PBM. In the next, what the PBM paid the pharmacy.

The gap between those two numbers was often wider than the Grand Canyon. In 35 percent of cases, the PBM was charging the insurer $105 for a drug they only paid the pharmacy $15 for. The pharmacy barely survives, the patient overpays, and the PBM reports record-breaking quarterly profits.

So, why doesn’t every pharmacist tell you the cash price? Beyond the time constraints, there is a technical hurdle. Their computer systems are designed to process insurance. To find the cash price, they often have to exit the primary workflow, run a separate “dummy” transaction, or check a different software entirely. It’s a friction point that saves the insurance industry billions of dollars every year.

The Act of Rebellion

I’ve started a new habit. I call it the “15-second pause.” Whenever a pharmacist tells me a copay that sounds even remotely high-anything over $25-I stop. I look them in the eye and ask: “Is there a lower price if I don’t use my insurance?”

The reaction is almost always the same. There is a brief moment of silence, a few rapid clicks of a mechanical keyboard, and then a revelation. Sometimes the difference is only $5. But sometimes, it’s $115.

There’s a certain irony in the fact that we have more technology than ever to track our health-smartwatches that monitor our heart rate every 5 minutes, apps that track our sleep-yet we are completely blind to the economics of the pills we swallow.

Taylor Z., with his vintage tools and his 1955 Parker fountain pen, actually has a better grasp of his “tools” than most of us have of our prescriptions. He knows the weight of the gold in the nib; we don’t even know the weight of the markup on our Metformin.

Choosing to Remain Sick

We also have to talk about the psychological toll. When a patient is told a medication is “too expensive” because of their insurance tier, they often just walk away. They don’t fill the script. Studies show that when a copay reaches $55 or higher, the abandonment rate triples.

People are literally choosing to remain sick because they believe their insurance has already given them the “best” price and they still can’t afford it. They don’t realize that the “best” price might be sitting right there, hidden behind a question they don’t know they’re allowed to ask.

It’s a systemic failure that feels personal. It’s the feeling of standing at a window and being told the view is $75, while the person next to you paid $5 because they didn’t bring a ticket. It defies the basic logic of how “membership” and “coverage” are supposed to work. In any other industry, this would be considered a scam. In healthcare, it’s just Tuesday.

The Color-Coded Alternative

The problem has become so pervasive that new types of pharmacies are springing up-places that refuse to take insurance at all, opting instead for a “cost-plus” model. They buy the drug for $15, add a $15 fee for the pharmacist’s time and overhead, and that’s it.

No clawbacks. No “gag clauses.” No 45-page contracts with PBMs. It’s the color-coded clarity that Taylor Z. craves. It’s a system where the ink actually ends up on the paper, not leaked all over the inside of the barrel.

Looking back, my own mistakes in this arena were born out of a misplaced trust in the “system.” I assumed that complexity equaled sophistication, and that sophistication equaled a better deal. I was wrong. The complexity was there to hide the “spread.” The sophistication was in the accounting, not the care.

If we want to fix this, it won’t be through a single piece of legislation or a new app. it will be through a million small moments of friction at the pharmacy counter. It will be through patients who refuse to just swipe the card. It will be through pharmacists who find the 5 seconds of courage to speak up.

It will be through people like Taylor, who look at a messy file system and decide it’s time to organize it by color until the patterns become impossible to ignore.